UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 未分化リンパ腫キナーゼ（ALK）融合癌遺伝子陽性非小細胞肺癌 anaplastic lymphoma kinase alk fusion oncogene positive non small cell lung cancer
- 2. 抗腫瘍療法関連肺毒性：分子標的剤 pulmonary toxicity associated with antineoplastic therapy molecularly targeted agents
- 3. 肝疾患を有する患者における化学療法による肝毒性および用量調整 chemotherapy hepatotoxicity and dose modification in patients with liver disease
- 4. 脳転移に対する全身療法 systemic therapy for brain metastases
- 5. 進行非小細胞肺癌に対する遺伝子型による個別治療 personalized genotype directed therapy for advanced non small cell lung cancer
English Journal
- Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: Design, synthesis, and structure-activity relationship study.
- Jiang X1, Zhou J2, Ai J3, Song Z4, Peng X2, Xing L4, Xi Y2, Guo J4, Yao Q5, Ding J2, Geng M6, Zhang A7.
- European journal of medicinal chemistry.Eur J Med Chem.2015 Oct 9;105:39-56. doi: 10.1016/j.ejmech.2015.10.005. [Epub ahead of print]
- Four series of tetracyclic benzo[b]carbazolone compounds possessing more rotatable bonds and higher molecular flexibility were designed by either inserting a linker within the C8-side chain or by opening the middle ketone ring on the basis of compound 5 (Alectinib, CH5424802). Compound 15b was ident
- PMID 26476749
- New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.
- Cameron L1, Solomon B.
- Current treatment options in oncology.Curr Treat Options Oncol.2015 Oct;16(10):49. doi: 10.1007/s11864-015-0367-z.
- OPINION STATEMENT: ALK rearrangements are present in 3-5% of patients with non-small cell lung cancer (NSCLC) and after epidermal growth factor receptor (EGFR) mutations represent the second molecular target in NSCLC to be validated through phase III clinical trials. The PROFILE 1014 international m
- PMID 26318457
- Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
- Yamamoto Y1, Okamoto I2,3, Otsubo K1, Iwama E1,4, Hamada N1, Harada T1, Takayama K1, Nakanishi Y1,5.
- Investigational new drugs.Invest New Drugs.2015 Oct;33(5):1148-50. doi: 10.1007/s10637-015-0284-9. Epub 2015 Sep 4.
- Alectinib, the second generation anaplastic lymphoma kinase (ALK) inhibitor, has significant potency in patients with ALK rearrangement positive non-small cell lung cancer (NSCLC), and its toxicity is generally well tolerable. We report a patient who developed severe acute interstitial lung disease
- PMID 26334220
Japanese Journal
- 肺癌診療ガイドライン2015 : 改訂のポイント
- 呼吸器内科 = Respiratory medicine 29(3), 259-262, 2016-03
- NAID 40020781898
- ALK阻害薬とバイオマーカー (特集 肺癌診断・治療の最前線)
- 呼吸器内科 = Respiratory medicine 29(3), 209-216, 2016-03
- NAID 40020781321
- アレクチニブによりGrade 4の好中球数減少を生じた1例―AF-001JP試験デザインに準じた用量減少による対応―
- 肺癌 56(2), 119-123, 2016
- NAID 130005152291
Related Pictures
★リンクテーブル★
| リンク元 | 「アレクチニブ」 |